30 Years of 340B: Policymakers Must Act Now to Prioritize Transparency, Accountability, and Oversight

With the 340B program marking its 30th anniversary in November, we must ask: who is benefiting from this drug pricing program? Is it truly supporting low-income communities as it was intended to?